A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaximin (Primary)
Indications Hepatic encephalopathy
Focus Registrational; Therapeutic Use
Acronyms RED-C-3132
Sponsors Bausch Health Companies

Most Recent Events

18 Nov 2024 According to a Bausch Health Companies media release, data from this study will be presented at the American Association for the Study of Liver Disease (AASLD), The Liver Meeting in San Diego, CA.
07 May 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
07 May 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight